Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A glimpse into the expert lexicon: Behavioural evidence from Aviation English.

Acta psychologica·2026

Same author

Translation of a physiologically-based pharmacokinetic model for dabigatran etexilate to the design of a safety and efficacy study in post-partum women.

British journal of clinical pharmacology·2025

Same author

The impact of <i>CYP2C9</i>, <i>VKORC1</i>, and <i>CYP4F2</i> polymorphisms on warfarin dose requirement in Saudi patients.

Frontiers in pharmacology·2025

Same author

A randomised crossover design study comparing the pharmacokinetics and pharmacodynamics of two single doses of oral aspirin (75 mg vs 150 mg) in pregnant women at risk of pre-eclampsia: a response to the letter to editor.

American journal of obstetrics and gynecology·2024

Same author

Comparing 75mg vs 150mg aspirin in pregnancy women at risk of preeclampsia.

American journal of obstetrics and gynecology·2024

Same author

A randomized crossover design study comparing the pharmacokinetics and pharmacodynamics of 2 single doses of oral aspirin (75 mg v 150 mg) in pregnant women at risk of preeclampsia: implications on assessing aspirin response and patient adherence to therapy.

American journal of obstetrics and gynecology·2024

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Pharmacogenetics of warfarin.

Farhad Kamali¹, Hilary Wynne

¹Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, UK. farhad.kamali@ncl.ac.uk

Annual Review of Medicine

|August 19, 2009

Summary

Pharmacogenetics, including CYP2C9 and VKORC1 gene variants, influences warfarin dosing. However, current evidence does not support pharmacogenetic-guided warfarin dosing for improved patient safety or efficacy.

Area of Science:

Pharmacology
Genetics
Clinical Medicine

Background:

Warfarin, an anticoagulant, has a narrow therapeutic index and significant dose variability.
Predicting optimal warfarin dosage is challenging, increasing risks of bleeding or clotting.

Purpose of the Study:

To review the role of genetic variations in warfarin dose requirements.
To assess the clinical utility of pharmacogenetics in guiding initial warfarin therapy.

Main Methods:

Review of existing studies on genetic polymorphisms (CYP2C9, VKORC1) and warfarin dose.
Analysis of evidence for pharmacogenetics-guided dosing outcomes.

Main Results:

CYP2C9 and VKORC1 gene polymorphisms significantly impact warfarin dose.

Related Experiment Videos

Last Updated: Jun 20, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Current small-scale studies show no proven benefit of pharmacogenetic-guided dosing on safety or efficacy.

Conclusions:

While genetic factors influence warfarin response, robust clinical evidence is lacking to establish pharmacogenomic-guided dosing in routine practice.
Further research is needed in diverse populations to confirm benefits, especially for extreme dose requirements.